Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 9/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315439 | 0.96 | HTR1A (0.36) | HTR1ACA1CA2CA4TRPV3 | |
| SCHEMBL16978964 | 0.84 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10 | |
| SCHEMBL15114207 | 0.84 | TRPV3 (0.38) | HTR1ACA1CA2CA4TRPV3 | |
| SCHEMBL15114205 | 0.78 | TRPV3 (0.35) | HTR1ATRPV3LTA4H | |
| SCHEMBL15114212 | 0.77 | TRPV3 (0.36) | HTR1ACA1CA2CA4TRPV3 | |
| SCHEMBL25825627 | 0.77 | TSHR (0.36) | CA1CA2CA4SMN1; SMN2 | |
| SCHEMBL13866403 | 0.77 | SSTR3 (0.31) | SMN1; SMN2HSD17B10 | |
| SCHEMBL8442337 | 0.76 | FUCA1 (0.42) | HTR1ACA1CA2CA4TRPV3 | |
| SCHEMBL8906921 | 0.76 | FUCA1 (0.42) | HTR1ACA1CA2CA4TRPV3 | |
| SCHEMBL8365576 | 0.76 | FUCA1 (0.42) | HTR1ACA1CA2CA4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871778-B2 | Substituted pyrimidine compounds and their use as SYK inhibitors | GENOSCO (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | Genosco Inc. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274242-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | SYK, BTK, LCK | HTR1A 3338/4885CA1 4749/4885CA2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.